Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06432777
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-29
First Post:
2024-05-14
Brief Title:
Recurrent Campylobacter Bacteraemia in Immunocompromised Patients
Sponsor:
Hospices Civils de Lyon
Organization:
Hospices Civils de Lyon
Study Overview
Official Title:
Recurrent Campylobacter Bacteraemia in Immunocompromised Patients a Retrospective Nationwide Study in France 2000-2025
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CABARET
Brief Summary:
Some rare cases of recurrent Campylobacter bacteraemia RCB exist with relapses months to years after an effective treatment and a negativation of all bacterial samples
As of today only around 20 cases have been described in the international literature for the last 30 years The cases are likely highly underreported
No study describes those recurrent Campylobacter bacteraemias at the scale of a country
The aim of this multicentre nationwide retrospective study is to describe their precise epidemiology in France for the last 25 years the immune profile of the patients the specificities of the bacteria involved the treatments received and the evolution of these infections
The perspective is to propose a standardization of the medical care of those patients mainly by describing the effective treatments and the explorations of the immune system which should be considered
As of today only around 20 cases have been described in the international literature for the last 30 years The cases are likely highly underreported
No study describes those recurrent Campylobacter bacteraemias at the scale of a country
The aim of this multicentre nationwide retrospective study is to describe their precise epidemiology in France for the last 25 years the immune profile of the patients the specificities of the bacteria involved the treatments received and the evolution of these infections
The perspective is to propose a standardization of the medical care of those patients mainly by describing the effective treatments and the explorations of the immune system which should be considered
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None